Exploring potential anti-inflammatory effects of medicinal cannabis.

Autor: Gurgenci T; Department Palliative and Supportive Care, 10th floor, Mater Health Services, Raymond Tce, South Brisbane, Queensland, 4101, Australia.; Mater Research Institute, University of Queensland, Brisbane, Queensland, Australia., Kijanka G; Queensland Micro- and Nanotechnology Centre, Griffith University, Nathan, Queensland, Australia., Greer R; Mater Research Institute, University of Queensland, Brisbane, Queensland, Australia.; Torus Research, Brisbane, Queensland, Australia., Huggett G; Department Palliative and Supportive Care, 10th floor, Mater Health Services, Raymond Tce, South Brisbane, Queensland, 4101, Australia., Good P; Department Palliative and Supportive Care, 10th floor, Mater Health Services, Raymond Tce, South Brisbane, Queensland, 4101, Australia.; Mater Research Institute, University of Queensland, Brisbane, Queensland, Australia.; Department of Palliative Care, St Vincent's Private Hospital Brisbane, Brisbane, Queensland, Australia., Moniruzzaman M; Mater Research Institute, University of Queensland, Brisbane, Queensland, Australia.; School of Pharmacy, The University of Queensland, Brisbane, Australia., Hardy J; Department Palliative and Supportive Care, 10th floor, Mater Health Services, Raymond Tce, South Brisbane, Queensland, 4101, Australia. janet.hardy@mater.org.au.; Mater Research Institute, University of Queensland, Brisbane, Queensland, Australia. janet.hardy@mater.org.au.
Jazyk: angličtina
Zdroj: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2023 Oct 14; Vol. 31 (12), pp. 629. Date of Electronic Publication: 2023 Oct 14.
DOI: 10.1007/s00520-023-08069-8
Abstrakt: Purpose: Inflammation is thought to play a key role in malignant disease and may play a significant part in the expression of cancer-related symptoms. Cannabidiol (CBD) is a bioactive compound in cannabis and is reported to have significant anti-inflammatory properties.
Method: Serial C-reactive protein (CRP) levels were measured in all participants recruited to a randomised controlled trial of CBD versus placebo in patients with symptoms related to advanced cancer. A panel of inflammatory cytokines was measured over time in a subset of these patients.
Results: There was no difference between the two arms in the trajectory of CRP or cytokine levels from baseline to day 28.
Conclusion: We were unable to demonstrate an anti-inflammatory effect of CBD in cancer patients.
Trial Registration: ANZCTR 26180001220257, registered 20/07/2018.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: